inupadenant + dostarlimab

**Inupadenant + dostarlimab** is a combination therapy under investigation for the treatment of advanced solid tumors, notably non-small cell lung cancer and other indications. Inupadenant is a small molecule antagonist of the adenosine A2A receptor, which blocks immunosuppressive signaling in the tumor microenvironment, making tumor cells more vulnerable to immune attack[3][4]. Dostarlimab is a monoclonal antibody that targets and inhibits the programmed cell death protein 1 (PD-1), serving as an immune checkpoint inhibitor and promoting anti-tumor immune responses[1][3]. Clinical trials are evaluating the safety, tolerability, and efficacy of this combination, both alone and with chemotherapy, to determine its effectiveness as a second-line therapy after prior immunotherapy has failed[3][5].

Other names

inupadenant HCl + dostarlimab